Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study

OBJECTIVES: Previous studies demonstrated equivalence in terms of efficacy and safety of biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching situations. Less is known about what happens when initiating a bsDMARD in a molecule naïve patient. The objectives of our study...

Descripción completa

Detalles Bibliográficos
Autores principales: Larid, Guillaume, Baudens, Guy, Dandurand, Alexis, Coquerelle, Pascal, Goeb, Vincent, Guyot, Marie Hélène, Marguerie, Laurent, Maury, Frédéric, Veillard, Eric, Houvenagel, Eric, Salmon, Jean-Hugues, Flipo, René-Marc, Gervais, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582272/
https://www.ncbi.nlm.nih.gov/pubmed/36275803
http://dx.doi.org/10.3389/fmed.2022.989514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582272/
https://www.ncbi.nlm.nih.gov/pubmed/36275803
http://dx.doi.org/10.3389/fmed.2022.989514

Ejemplares similares